CY2018018I2 - Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα - Google Patents

Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Info

Publication number
CY2018018I2
CY2018018I2 CY2018018C CY2018018C CY2018018I2 CY 2018018 I2 CY2018018 I2 CY 2018018I2 CY 2018018 C CY2018018 C CY 2018018C CY 2018018 C CY2018018 C CY 2018018C CY 2018018 I2 CY2018018 I2 CY 2018018I2
Authority
CY
Cyprus
Prior art keywords
antibodies
treatment
mediterranean fever
familial mediterranean
familial
Prior art date
Application number
CY2018018C
Other languages
English (en)
Other versions
CY2018018I1 (el
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2018018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2018018I1 publication Critical patent/CY2018018I1/el
Publication of CY2018018I2 publication Critical patent/CY2018018I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
CY2018018C 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα CY2018018I2 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
EP10181100A EP2332577A1 (en) 2005-10-26 2006-10-24 Novel use of IL-1beta compounds
EP06826560A EP1940465B1 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies

Publications (2)

Publication Number Publication Date
CY2018018I1 CY2018018I1 (el) 2018-12-12
CY2018018I2 true CY2018018I2 (el) 2018-12-12

Family

ID=37806690

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20121100867T CY1113378T1 (el) 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY2013046C CY2013046I2 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20121100867T CY1113378T1 (el) 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY2013046C CY2013046I2 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Country Status (28)

Country Link
US (9) US8105587B2 (el)
EP (5) EP2848258B1 (el)
JP (4) JP2009513645A (el)
KR (3) KR101518064B1 (el)
CN (2) CN101291693B (el)
AU (1) AU2006306280B2 (el)
BR (1) BRPI0617830B8 (el)
CA (3) CA2898369C (el)
CY (4) CY1113378T1 (el)
DK (2) DK1940465T3 (el)
ES (3) ES2944067T3 (el)
HU (2) HUE036973T2 (el)
IL (4) IL190545A (el)
JO (2) JO2826B1 (el)
LT (3) LT2848258T (el)
LU (2) LU92326I2 (el)
MA (1) MA29919B1 (el)
NO (2) NO345888B1 (el)
NZ (1) NZ567222A (el)
PH (2) PH12013501287B1 (el)
PL (2) PL1940465T3 (el)
PT (2) PT1940465E (el)
RU (2) RU2468817C2 (el)
SI (2) SI1940465T1 (el)
TN (1) TNSN08189A1 (el)
TR (1) TR201802449T4 (el)
TW (3) TWI388335B (el)
WO (1) WO2007050607A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2848258B1 (en) * 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
AU2012203931B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
EP3406263A1 (en) * 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
TW201124427A (en) * 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
AU2011252883B2 (en) * 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
WO2012121775A2 (en) * 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
EP3426775A1 (en) 2016-03-10 2019-01-16 Novartis AG Chemically modified messenger rna's
US11162943B2 (en) 2017-05-31 2021-11-02 Prometheus Biosciences Inc. Methods for assessing mucosal healing in Crohn's disease patients
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
CN112584857A (zh) * 2018-05-09 2021-03-30 诺华股份有限公司 卡那吉努单抗的用途
WO2020128636A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
JP2022514087A (ja) 2018-12-21 2022-02-09 ノバルティス アーゲー ＩＬ－１β結合抗体の使用
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
EP4464329A4 (en) * 2022-01-10 2025-06-11 GI Innovation, Inc. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES, CONTAINING A GLUCAGON-LIKE PEPTIDE-1 AND AN INTERLEUKIN-1 RECEPTOR ANTAGONIST

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
EP0690673A4 (en) 1993-12-14 1996-05-29 Univ Pittsburgh SYSTEMIC GENETIC TREATMENT OF TISSUE DISEASES
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
JP2003500005A (ja) 1999-02-10 2003-01-07 インターリューキン ジェネティックス インコーポレイテッド ＩＬ−１β遺伝子の突然変異に基づく治療および診断
DK1210320T3 (da) * 1999-07-16 2005-01-31 Leo Pharma As Aminobenzofenoner som inhibitorer for IL-1beta og TNF-alfa
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP2241328A1 (en) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
SG159378A1 (en) 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
EP1423432A4 (en) * 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
EP1450837A4 (en) * 2001-08-07 2006-01-04 Immunex Corp INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
ES2385823T3 (es) 2001-12-01 2012-08-01 Iskra Wind Turbines Ltd. Generador de corriente alterna síncrono que incorpora un mecanismo de frenado
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
JP2005519917A (ja) 2002-02-01 2005-07-07 オメロス コーポレイション 軟骨分解の全身阻害のための組成物および方法
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
CA2474360A1 (en) * 2002-02-11 2003-08-21 Arkion Life Sciences Llc Purified cytokine inhibitory factor
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
AU2004290413A1 (en) 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring IL-18
US20080207613A1 (en) 2004-01-12 2008-08-28 Cytopia Research Pty Ltd Selective Kinase Inhibitors
AU2005216298B2 (en) * 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
AU2005249570B2 (en) * 2004-06-04 2011-06-16 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
JP2009501128A (ja) 2005-01-20 2009-01-15 ユニバーシティー オブ ロチェスター 炎症疾患および炎症障害の研究および処置のための組成物および方法
EP2371967B1 (en) 2005-03-18 2015-06-03 DSM IP Assets B.V. Production of carotenoids in oleaginous yeast and fungi
ES2569917T3 (es) 2005-06-21 2016-05-13 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
EP2848258B1 (en) * 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies

Also Published As

Publication number Publication date
EP3332807B1 (en) 2023-02-22
WO2007050607A2 (en) 2007-05-03
IL190545A (en) 2016-09-29
HUE036973T2 (hu) 2018-08-28
TW201617097A (zh) 2016-05-16
PT1940465E (pt) 2012-10-03
US20210147533A1 (en) 2021-05-20
IL277406A (en) 2020-11-30
MA29919B1 (fr) 2008-11-03
LTC1940465I2 (lt) 2017-12-11
JP2013166757A (ja) 2013-08-29
DK1940465T3 (da) 2012-10-22
HK1252316A1 (en) 2019-05-24
JOP20140120B1 (ar) 2021-08-17
SI2848258T1 (en) 2018-03-30
KR101749388B1 (ko) 2017-06-20
DK2848258T3 (en) 2018-03-19
JP2017206552A (ja) 2017-11-24
TWI626056B (zh) 2018-06-11
HUS1800025I1 (hu) 2018-07-30
EP4218815A3 (en) 2024-03-27
RU2008120625A (ru) 2010-01-20
ES2944067T3 (es) 2023-06-19
US20150322148A1 (en) 2015-11-12
LTPA2018506I1 (lt) 2018-06-25
TW201302220A (zh) 2013-01-16
US20170218063A1 (en) 2017-08-03
CY2018018I1 (el) 2018-12-12
KR20150013834A (ko) 2015-02-05
TR201802449T4 (tr) 2018-03-21
IL245387B (en) 2019-09-26
EP2848258A1 (en) 2015-03-18
LTC2848258I2 (lt) 2019-08-12
CY1120018T1 (el) 2018-12-12
CA2898369A1 (en) 2007-05-03
LU92326I2 (fr) 2014-02-05
US20260125463A1 (en) 2026-05-07
US9649377B2 (en) 2017-05-16
NZ567222A (en) 2011-07-29
EP3332807A2 (en) 2018-06-13
IL190545A0 (en) 2008-11-03
CN101291693B (zh) 2012-10-03
BRPI0617830A2 (pt) 2011-08-09
PT2848258T (pt) 2018-03-20
JP2009513645A (ja) 2009-04-02
EP1940465A2 (en) 2008-07-09
CA2963828A1 (en) 2007-05-03
HK1204767A1 (en) 2015-12-04
US8409576B2 (en) 2013-04-02
US20130171167A1 (en) 2013-07-04
ES2662420T3 (es) 2018-04-06
RU2012133522A (ru) 2014-02-20
US20080286266A1 (en) 2008-11-20
NO345140B1 (no) 2020-10-12
WO2007050607A3 (en) 2007-06-28
BRPI0617830B1 (pt) 2020-10-20
ES2389110T3 (es) 2012-10-23
CA2626214C (en) 2016-06-21
AU2006306280A1 (en) 2007-05-03
TWI537003B (zh) 2016-06-11
EP2332577A1 (en) 2011-06-15
PH12013501287A1 (en) 2016-02-01
TWI388335B (zh) 2013-03-11
CY2013046I1 (el) 2015-11-04
PH12020500559A1 (en) 2021-06-14
US20180201674A1 (en) 2018-07-19
LU92326I9 (el) 2019-01-16
PH12013501287B1 (en) 2016-02-01
AU2006306280B2 (en) 2010-06-17
IL258983B (en) 2020-10-29
KR101518064B1 (ko) 2015-05-06
HK1121041A1 (en) 2009-04-17
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
RU2571563C2 (ru) 2015-12-20
EP4218815A2 (en) 2023-08-02
IL245387A0 (en) 2016-06-30
LT2848258T (lt) 2018-02-26
EP2848258B1 (en) 2017-12-13
CY1113378T1 (el) 2015-11-04
EP3332807A3 (en) 2018-06-20
JP6286403B2 (ja) 2018-02-28
NO345888B1 (no) 2021-09-27
RU2468817C2 (ru) 2012-12-10
EP1940465B1 (en) 2012-08-01
SI1940465T1 (sl) 2012-10-30
PL1940465T3 (pl) 2013-01-31
TNSN08189A1 (en) 2009-10-30
IL258983A (en) 2018-06-28
NO20200810A1 (no) 2008-07-22
JP2016020377A (ja) 2016-02-04
JP6061747B2 (ja) 2017-01-18
KR20080059598A (ko) 2008-06-30
BRPI0617830B8 (pt) 2021-05-25
CA2898369C (en) 2017-06-20
CN101291693A (zh) 2008-10-22
NO20082344L (no) 2008-07-22
CY2013046I2 (el) 2015-11-04
US8105587B2 (en) 2012-01-31
PL2848258T3 (pl) 2018-06-29
JO2826B1 (en) 2014-09-15
CN102861332A (zh) 2013-01-09
CA2626214A1 (en) 2007-05-03
TW200803898A (en) 2008-01-16
LUC00078I2 (fr) 2018-08-14
US20120039910A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
CY2018018I1 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
HUS2100053I1 (hu) Interleukin-13-antitest-készítmény
CY2016029I1 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
HRP20220755T3 (hr) Anti-gm-csf antitijela i njihova uporaba
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
PT1943264E (pt) Análogos de oligonucleosídeos incorporando neles 5-azacitosina
NO20076607L (no) TWEAK - bindende antistoff
HRP20150176T1 (xx) Protutijela protiv miostatina
DK1964852T3 (da) Anti-ilt7-antistof
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0814003A2 (pt) Formulações de anticorpo
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DE602006017373D1 (de) Madcam-antikörper
EP1856492A4 (en) ULTRASENSITIVE SPECTROPHOTOMETER
EP1906944A4 (en) SKI ANDRIN-B-PREPARATION
NO20055643D0 (no) Preparation of lodixanol
BRPI0916092A2 (pt) "isoformas específicas de anticorpos anti-her4"
NO20052035D0 (no) Stopemasse
DE112006001562A5 (de) Linearachse
ATE457365T1 (de) Matrize mit kleinen näpfchenartigen vertiefungen
EP1942979A4 (en) Airway balloon dilator
FI20055133A0 (fi) Iskulaite
ES1061344Y (es) Pañal